Treatment of essential HTN. Reduction of CV morbidity in adults w/ manifest atherothrombotic CV disease (history of CHD, stroke or peripheral arterial disease) or type 2 DM w/ documented target organ damage.
AdultTreatment of essential HTN 40 mg once daily. Max: 80 mg once daily. Prevention of CV morbidity 80 mg once daily. Mild to moderate hepatic impairment Max: 40 mg once daily.
Hepatic impairment. Renovascular HTN. Monitor K & creatinine levels in patients w/ impaired renal function. Intravascular hypovolaemia should be corrected prior to treatment. Dual blockage of RAAS. Severe CHF, primary aldosteronism, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Antidiabetics & insulin. Monitor serum K in patients at risk of hyperkalaemia. Rare hereditary condition of fructose intolerance. Ethnic differences. Childn <18 yr.
Sign Out
